Health-state utilities in long-term advanced melanoma survivors comparable with the general population
2023 · Quality of Life Research · 5 citations
https://doi.org/10.1007/s11136-023-03427-9
M
Mees Egeler
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
13
Papers
83
Citations
4
h-index
3
i10-index
Mees Egeler is an academic researcher from Dutch Cancer Society. The author has contributed to research in topics: CAR-T cell therapy research & Cancer Immunotherapy and Biomarkers & Cutaneous Melanoma Detection and Management. The author has an h-index of 4, co-authored 12 publications.
ORCID: 0000-0002-9905-2809Papers by this author
worksQuality of life issues faced by patients with keratinocyte cancer: A systematic review
2024 · EJC Skin Cancer · 3 citations
https://doi.org/10.1016/j.ejcskn.2024.100022
“One more chance to survive”: the experiences of patients with advanced melanoma and their partners with tumor-infiltrating lymphocyte therapy—a qualitative study and recommendations for future care
2023 · Journal of Cancer Survivorship · 2 citations
https://doi.org/10.1007/s11764-023-01452-8
MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study
2026 · The Lancet Oncology · 0 citations
https://doi.org/10.1016/s1470-2045(25)00707-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat